Study of Utidelone Capsules for Platinum-Resistant Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an oral chemotherapy called Utidelone for people with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. It aims to see if this drug can help when standard options have failed or are not tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer has returned or worsened within 6 months of your last platinum-based chemotherapy (like carboplatin or cisplatin).
- You have at least one tumor that can be measured on a scan and are well enough to be up and about (ECOG score 0 or 1).
- You have had 1 to 3 prior lines of systemic treatment (maintenance therapy like Avastin or PARP inhibitors counts as part of the previous line).
- Your blood counts and kidney/liver function meet specific levels, and you are not pregnant or breastfeeding.
- You have not used other anti-cancer treatments within 4 weeks (or certain drugs within 2 weeks) before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests utidelone capsules as a single treatment for people with certain advanced cancers, including stomach, bile duct, ovarian, esophageal, liver, colorectal, and cervical cancer. It is for those whose cancer has not responded to standard therapy and may offer a new option.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
This study tests a new drug, Raludotatug Deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as ongoing treatment after initial chemotherapy for recurrent ovarian cancer. It aims to see if this maintenance treatment helps keep the cancer from coming back longer.
This trial tests a new targeted therapy called DT2216 combined with the chemotherapy paclitaxel for people with ovarian cancer that is resistant to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two oral drugs (Utidelone and Fruquintinib) for ovarian cancer that has stopped responding to platinum chemotherapy. It may offer a new option when standard treatments stop working.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.